Evidence map›Paper›PMID 30788170›Full record

ReviewJournal of gastrointestinal oncology2019

Gastrointestinal stromal tumors: a comprehensive review.

Trisha M Parab, Michael J DeRogatis, Alexander M Boaz, Salvatore A Grasso, Paul S Issack, David A Duarte, Olivier Urayeneza, Saloomeh Vahdat, Jian-Hua Qiao, Gudata S Hinika

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of gastrointestinal oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 186 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
186citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

186 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review

126 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Trisha M ParabDepartment of Surgery, Dignity Health California Hospital Medical Center, Los Angeles, CA, USA.
Michael J DeRogatisDepartment of Surgery, Dignity Health California Hospital Medical Center, Los Angeles, CA, USA.
Alexander M BoazDepartment of Surgery, Dignity Health California Hospital Medical Center, Los Angeles, CA, USA.
Salvatore A GrassoDepartment of Surgery, Dignity Health California Hospital Medical Center, Los Angeles, CA, USA.
Paul S IssackDepartment of Orthopaedic Surgery, New York-Presbyterian Hospital, New York, NY, USA.
David A DuarteDepartment of Surgery, Dignity Health California Hospital Medical Center, Los Angeles, CA, USA.
Olivier UrayenezaDepartment of Surgery, Dignity Health California Hospital Medical Center, Los Angeles, CA, USA.
Saloomeh VahdatDepartment of Pathology, Dignity Health California Hospital Medical Center, Los Angeles, CA, USA.
Jian-Hua QiaoDepartment of Pathology, Dignity Health California Hospital Medical Center, Los Angeles, CA, USA.
Gudata S HinikaDepartment of Surgery, Dignity Health California Hospital Medical Center, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract associated with high rates of malignant transformation. Most GISTs present asymptomatically. They are best identified by computed tomography (CT) scan and most stain positive for CD117 (C-Kit), CD34, and/or DOG-1. There have been many risk stratification classifications systems which are calculated based on tumor size, mitotic rate, location, and perforation. The approaches to treating GISTs are to resect primary low-risk tumors, resect high-risk primary or metastatic tumors with imatinib 400 mg daily for 12 months, or if the tumor is unresectable, neoadjuvant imatinib 400 mg daily followed by surgical resection is recommended. Sunitinib is required for KIT exon 9, 13, and 14 mutations, while ponatinib is used for exon 17 mutations and regorafenib for highly refractory tumors. High-risk tumors should be monitored for recurrence with serial abdominal CT scans. Radiofrequency ablation has shown to be effective when surgery is not suitable. Newer therapies of ipilimumab, nivolumab, and endoscopic ultrasound alcohol ablation have shown promising results. This report addresses the epidemiology, clinical presentation, diagnostic imaging, histologic diagnosis, classification and risk stratification, staging and grading, surgical treatment, adjuvant treatment, and metastasis of GISTs.

Indexed as

Gastrointestinal stromal tumor (GIST)outcomeprognosisrisk classificationtyrosine kinase receptor inhibitor (TKI)

Identifiers

PMID30788170
PMCPMC6351301

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.